MICHAEL SIMS: Open Payments
NPI 1427053180 · LONGVIEW, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,453 in 93 payments from 22 companies in 2025. Trend: 2023 $2,184 · 2024 $1,567 · 2025 $1,453
Food & beverage: $1,453
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 15 | $194 |
| ABBVIE INC. | 14 | $182 |
| Novo Nordisk Inc | 11 | $178 |
| GlaxoSmithKline, LLC. | 15 | $150 |
| AstraZeneca Pharmaceuticals LP | 7 | $148 |
| Corcept Therapeutics | 4 | $124 |
| Axsome Therapeutics, Inc. | 4 | $93 |
| PFIZER INC. | 5 | $78 |
| Astellas Pharma US Inc | 2 | $44 |
| Abbott Laboratories | 2 | $41 |
Products named: TRELEGY ELLIPTA, JARDIANCE, Korlym, AIRSUPRA, VRAYLAR, Rybelsus, Wegovy, Symbravo.
Industry payments across TX — which companies pay providers there.
